Binimetinib

Fact of Medicine
Brand Name: Mektovi
Innovator Brand Name: Mektovi
API: Binimetinib
Packaging: 180 Tablets
Strength: 15mg
Manufacturer Name: Array Biopharma, Inc.

Get Price

Description

Binimetinib Medication:

Mektovi (Binimetinib) is a kinase inhibitor used along with encorafenib, to treat patients with unresectable/metastatic melanoma with a mutation named BRAF V600E or V600K.

Dosage: The recommended binimetinib dose is 45 mg, administered orally twice daily, about 12 hours apart, along with drug encorafenib until the disease is progressive or in occurence of unacceptable toxicity. Binimetinib may be administered either with or without food. Do not take any missed dose of binimetinib within 6 hours of the next dose. Do not administer an additional dose in case vomiting occurs after administration of binimetinib dosage but carry on with the next scheduled dose.

Side Effects: The most commonly reported binimetinib side effects along with encorafenib

  • include:
  • Fatigue
  • Nausea
  • Diarrhea
  • Vomiting
  • Abdominal pain

Warnings and Precautions:

  • It is recommended to confirm the presence of a BRAF V600E or V600K mutation in tumor specimens before starting binimetinib 15 mg therapy.
  • Recipients with cardiovascular risk factors should be monitored closely while on mektovi dosage.
  • Patients should be monitored for liver laboratory tests prior to the initiation of binimetinib 15 mg tablet, monthly during treatment.
  • Monitor patients for CPK as well as creatinine levels before starting encorafenib-binimetinib, periodically during treatment.
  • Findings indicate that the mektovi 15 mg can be responsible for causing fetal harm if administered to a pregnant woman.
  • Due to the potential for serious side effects from encorafenib and binimetinib in breastfed infants, women should not breastfeed during therapy and for 3 days after the last dose.

More info

Storage: Store Mektovi (binimetinib tablets) at temperature 20°C to 25°C (68°F to 77°F). The excursions permitted between 15°C and 30°C (59°F and 86°F). Availability in India: The Indian Pharma helps connect buyers with suppliers who can ship the MEKTOVI at the global level as per the needs of buyer’s. The Indian Pharma provides guarantee of quality as well as delivery for the MEKTOVI Tablets. Buying Procedure: In order to buy MEKTOVI, you can contact us at our Toll-free number 1800 889 1064 or on WhatsApp number +919650877511 or an Email to us at: info@theindianpharma.com along with your valid Identity Proof, Legitimate Prescription letter and Medical Reports. Conclusion: Certain findings demonstrated the superiority of combination of encorafenib and binimetinib over single-agent vemurafenib, and has established this combination therapy as a standard of care in the treatment of BRAF V600 mutant melanoma with targeted therapy. The median OS and progression free survival for this combination therapy were both about double that of vemurafenib, with the combination having a manageable safety profile.

FAQ

What is Mektovi? Mektovi is a prescription drug used together with encorafenib for the treatment of patients with unresectable or metastatic melanoma. What does Mektovi contain as an active substance? The medication Mektovi specifically contains the active substance Binimetinib. Is Mektovi chemotherapy? Mektovi and Braftovi, both are the targeted therapies that, when administered together, can be used for the treatment of melanoma. Is Binimetinib an FDA approved drug? Yes, Binimetinib is an FDA approved drug. How much does mektovi cost? The mektovi price usually may vary depending on the wholesaler/pharmacy you visit and of course the brand you choose. What is the best price for Binimetinib? Please contact Toll-free: +91 1800 889 1064|+919650877511 for binimetinib price in India. We take guarantee of quality as well as delivery anywhere in the world as per the buyer’s requirements. Can I get Mektovi (Binimetinib) even if I am not based in India? The Indian Pharma helps patients in accessing or importing Mektovi (Binimetinib), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.

Reviews

There are no reviews yet.

Be the first to review “Binimetinib”

Your email address will not be published.

×